Raymond James & Associates’s ChemoCentryx, Inc. CCXI Stock Holding History

Raymond James & Associates’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-73,400	Closed	-$222K	–	4186
2022 Q2	$222K	Sell	73,400 -43,400	-37%	-$957K	﹤0.01%	3439
2022 Q1	$543K	Buy	+116,800	New	+$3.28M	﹤0.01%	3026

Other funds holding CCXI

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Raymond James & Associates's CCXI Position: Q4 2022 in Review

Raymond James & Associates sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 41,068 shares — an estimated $2.12M sold.

Raymond James & Associates first reported a position in CCXI in Q4 2018 and held it in 16 quarters. The position peaked at $14.1M in Q4 2020. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.

Raymond James & Associates reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
Raymond James & Associates sold 41,068 ChemoCentryx, Inc. shares in Q4 2022, an estimated $2.12M.
Raymond James & Associates first reported a position in ChemoCentryx, Inc. in Q4 2018 and held it in 16 quarters.
Raymond James & Associates's ChemoCentryx, Inc. position peaked at $14.1M in Q4 2020.
1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.

Based on Raymond James & Associates's 13F filing for Q4 2022, filed 8 Feb 2023.